A new inter partes review has been filed at the Patent Trial and Appeal Board against ResMed Corp., opening another front in the increasingly important fight over respiratory and sleep-therapy technology. The petition, docketed as IPR2026-00341 and filed June 12, 2026, places at issue the validity of a ResMed patent before the PTAB, where petitioners can seek cancellation of issued patent claims based on prior art patents and printed publications.

At this early stage, the publicly available docket information identifies the proceeding as Resmed Corp., but does not yet provide the full set of petition details typically most relevant to practitioners, including the patent number, the petitioner’s identity, and the specific prior-art combinations asserted.

A new inter partes review proceeding at the Patent Trial and Appeal Board could draw close attention from patent owners, challengers, and counsel following the medical technology sector. In IPR2026-00341, filed June 12, 2026, the petition is styled Resmed Corp., signaling that ResMed is involved in a fresh PTAB dispute over the validity of an issued patent.

At this early stage, the public docket identifies the proceeding but may not yet fully reflect all underlying petition details, including the specific patent number, all real parties in interest, and the complete list of asserted prior-art grounds.